Trials / Terminated
TerminatedNCT02847052
Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (actual)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non interventional study |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2022-03-16
- Completion
- 2022-03-16
- First posted
- 2016-07-27
- Last updated
- 2022-03-17
Source: ClinicalTrials.gov record NCT02847052. Inclusion in this directory is not an endorsement.